CytRx Corp. Daily Stock Analysis

Daily Stock Analysis, CYTR, CytRx Corp, priceseries

CytRx Corp. Daily Stock Analysis
Stock Information
Open
0.40
Close
0.39
High
0.40
Low
0.36
Previous Close
0.41
Daily Price Gain
-0.02
YTD High
0.69
YTD High Date
Jan 11, 2022
YTD Low
0.31
YTD Low Date
Mar 3, 2022
YTD Price Change
-0.17
YTD Gain
-30.36%
52 Week High
4.70
52 Week High Date
Jun 10, 2021
52 Week Low
0.31
52 Week Low Date
Mar 3, 2022
52 Week Price Change
-3.20
52 Week Gain
-89.14%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 9. 2017
2.46
Jan 18. 2017
2.60
6 Trading Days
5.81%
Link
LONG
Apr 19. 2017
3.12
Apr 20. 2017
3.34
1 Trading Days
6.92%
Link
LONG
Apr 21. 2017
3.68
Apr 27. 2017
4.04
4 Trading Days
9.87%
Link
LONG
May 25. 2017
3.65
Jun 5. 2017
4.16
6 Trading Days
13.91%
Link
LONG
Oct 31. 2017
2.18
Nov 1. 2017
2.38
1 Trading Days
9.45%
Link
LONG
Jan 22. 2018
1.83
Jan 29. 2018
1.96
5 Trading Days
7.26%
Link
LONG
Dec 10. 2020
0.77
Dec 17. 2020
0.90
5 Trading Days
16.56%
Link
LONG
Dec 21. 2020
1.05
Jan 4. 2021
1.48
8 Trading Days
40.70%
Link
LONG
Jan 12. 2021
1.96
Jan 25. 2021
2.27
8 Trading Days
15.99%
Link
LONG
Feb 4. 2021
2.25
Feb 25. 2021
3.34
14 Trading Days
48.28%
Link
LONG
Apr 26. 2021
2.24
May 5. 2021
2.48
7 Trading Days
10.93%
Link
Company Information
Stock Symbol
CYTR
Exchange
NasdaqCM
Company URL
http://www.cytrx.com
Company Phone
310-826-5648
CEO
Steven A. Kriegsman
Headquarters
California
Business Address
11726 SAN VICENTE BOULEVARD, SUITE 650, LOS ANGELES, CA 90049
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000799698
About

CytRx Corp. operates as a biopharmaceutical research and development company specializing in oncology. It provides clinical development of aldoxorubicin oncology pipeline for the treatment of cancer. The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.

Description

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company's product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing anti-cancer drug conjugates, which utilizes its Linker Activated Drug Release technology. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading